InvestLog
LIMN Liminatus Pharma, Inc. Class A Common Stock logo

LIMN Liminatus Pharma, Inc. Class A Common Stock

Healthcare
$0.17-31.14%ClosedMarket Cap: $4.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-30.35

P/S

0.00

EV/EBITDA

-0.38

DCF Value

$-0.05

FCF Yield

-263.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

215.7%

ROA

-394.3%

ROIC

-283.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-1.1M$—
Q4 null$0.00$-8.2M$—
FY null$0.00$-10.2M$—
Q3 null$0.00$-1.8M$—

Trading Activity

Insider Trades

View All
Iris Acquisition Holdings LLC10 percent owner
SellFri Aug 15
Lemons II Philip Waynedirector:
SellWed Jul 23
Baek Richard JaiHwandirector:
SellMon Jul 21
KH Feelux Co., Ltd10 percent owner
SellFri Jun 27
Valetudo Therapeutics LLC10 percent owner
SellMon Jun 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.74

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Peers

ATHE logoATHEBTAI logoBTAIDYAI logoDYAIEVAX logoEVAXGBIO logoGBIOJSPR logoJSPRMAIA logoMAIAMURA logoMURANNVC logoNNVCSABS logoSABS